Provided by Tiger Fintech (Singapore) Pte. Ltd.

PTC Therapeutics

44.23
+1.724.05%
Post-market: 44.400.1700+0.38%18:23 EDT
Volume:1.54M
Turnover:68.48M
Market Cap:3.51B
PE:5.89
High:46.03
Open:44.29
Low:43.95
Close:42.51
Loading ...

PTC Therapeutics Inc - Novartis to Assume Global Development and Commercial Responsibilities

THOMSON REUTERS
·
02 Dec 2024

PTC Therapeutics to sell Priority Review Voucher for $150M

TipRanks
·
28 Nov 2024

RBC Capital Remains a Hold on PTC Therapeutics (PTCT)

TIPRANKS
·
28 Nov 2024

BUZZ-PTC Therapeutics falls after scrapping development of ALS drug

Reuters
·
28 Nov 2024

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

Benzinga
·
27 Nov 2024

TD Cowen Remains a Hold on PTC Therapeutics (PTCT)

TIPRANKS
·
27 Nov 2024

PTC Therapeutics Sells Priority Review Voucher for $150M

TIPRANKS
·
27 Nov 2024

PTC Therapeutics to Sell Rare Pediatric Disease Voucher for $150 Million

MT Newswires Live
·
27 Nov 2024

PTC Therapeutics price target raised to $52 from $48 at Baird

TIPRANKS
·
27 Nov 2024

BRIEF-PTC Therapeutics Enters Into Agreement To Sell Priority Review Voucher For $150 Mln

Reuters
·
27 Nov 2024

PTC Therapeutics Inc - to Sell Priority Review Voucher for $150 Million

THOMSON REUTERS
·
27 Nov 2024

PTC Therapeutics: Sell Rating Due to Unmet Trial Goals and Overvaluation Concerns

TIPRANKS
·
27 Nov 2024

PTC Therapeutics: Growth Potential Amid Strategic Shifts and Upcoming Catalysts

TIPRANKS
·
27 Nov 2024

BRIEF-Ptc Therapeutics Announces Topline Results Of Cardinals Trial Of Utreloxastat In ALS Patients

Reuters
·
27 Nov 2024

PTC Therapeutics' Amyotrophic Lateral Sclerosis Trial Fails to Meet Endpoints; Shares Fall After Hours

MT Newswires Live
·
27 Nov 2024

PTC Therapeutics to End Development of ALS Treatment

Dow Jones
·
27 Nov 2024

UPDATE 1-PTC Therapeutics discontinues development of ALS drug after trial failure

Reuters
·
27 Nov 2024

PTC Therapeutics' ALS drug fails mid-stage trial

Reuters
·
27 Nov 2024

PTC Therapeutics: Phase 2 CardinALS study did not meet its primary endpoint

TIPRANKS
·
27 Nov 2024

PTC Therapeutics Inc - Study Failed to Meet Primary and Secondary Efficacy Endpoints

THOMSON REUTERS
·
27 Nov 2024